key: cord-0706758-hcugb1pc
authors: Muñoz-Rivas, Nuria; Abad-Motos, Ane; Mestre-Gómez, Beatriz; Sierra-Hidalgo, Fernando; Cortina-Camarero, Cristina; Lorente-Ramos, Rosa María; Torres-Rubio, Pedro; Arranz-García, Paz; Franco-Moreno, Ana Isabel; Gómez-Mariscal, Eloy; Mauleón-Fernández, Cristina; Alonso-García, Soledad; Rogado, Jacobo; Saez-Vaquero, Teresa; Such-Diaz, Ana; Ryan, Pablo; Moya-Mateo, Eva; Martín-Navarro, Juan A.; Hernández-Rivas, Jose Angel; Torres-Macho, Juan; Churruca, Juan
title: Systemic thrombosis in a large cohort of COVID-19 patients despite thromboprophylaxis: a retrospective study
date: 2021-01-07
journal: Thromb Res
DOI: 10.1016/j.thromres.2020.12.024
sha: 636ca5cd182c076d501a38a1bf71551e55e24790
doc_id: 706758
cord_uid: hcugb1pc

Background Incidence of thrombotic events associated to Coronavirus disease-2019 (COVID-19) is difficult to assess and reported rates differ significantly. Optimal thromboprophylaxis is unclear. Objectives We aimed to analyze the characteristics of patients with a confirmed thrombotic event including inflammatory and hemostatic parameters, compare patients affected by arterial vs venous events and examine differences between survivors and non-survivors. We reviewed compliance with thromboprophylaxis and explored how the implementation of a severity-adjusted protocol could have influenced outcome. Methods Single-cohort retrospective study of COVID-19 patients admitted, from March 3 to May 3, to the Infanta Leonor University Hospital in Madrid, epicenter of the Spanish outbreak. Results Among 1,127 patients, 80 thrombotic events were diagnosed in 69 patients (6.1% of the entire cohort). 43 patients (62%) suffered venous thromboembolism, 18 (26%) arterial events and 6 (9%) concurrent venous and arterial thrombosis. Most patients (90%) with a confirmed thrombotic event where under low-molecular-weight heparin treatment. Overt disseminated intravascular coagulation (DIC) was rare. Initial ISTH DIC score and pre-event CRP were significantly higher among non-survivors. In multivariate analysis, arterial localization was an independent predictor of mortality (OR=18, 95% CI: 2.4-142, p<.05). Conclusions Despite quasi-universal thromboprophylaxis, COVID-19 lead to a myriad of arterial and venous thrombotic events. Considering the subgroup of patients with thrombotic episodes, arterial events conferred very poor prognosis and an ISTH DIC score ≥3 at presentation was identified as a potential predictor of mortality. Severity-adjusted thromboprophylaxis seemed to decrease the number of events and could have influenced mortality. Randomized controlled trials are eagerly awaited.

On December 31, 2019, Wuhan authorities reported 27 pneumonia cases of unknown etiology [1] . A week later, a virus of the family Coronaviridae was identified as the agent causing the cluster [2] , and it rapidly spread [3] . On March 11, 2020 , the WHO declared the pandemia [4] . Since the beginning of the worldwide outbreak, over 15 million cases have been reported and mortality rate differs substantially among countries, with a global world rate of 5% but as high as 20% in some areas. As of July 16, 2020, Spain has reported 260,000 cases and 28,400 deaths, resulting in a 10% mortality rate [5] [6] [7] . Initial reports from China described the clinical picture of the Coronavirus disease of 2019 (COVID-19) [8] [9] [10] [11] . It soon came clear that the interaction between the virus and the immune system was key in the pathogenesis, and multiple reports proposed a hyperinflammatory state, that could explain many of the clinical and laboratory findings. Interestingly, even though prominent abnormalities of hemostatic parameters were soon described as common and related to poor prognosis [12] [13] [14] [15] [16] [17] , thrombotic events were not brought to light during the early phase of the pandemic.

By the end of March, the clinical relevance of coagulation impairment potentially reflecting pulmonary micro or macrothrombosis and the association of the disease with a high thrombotic risk began to emerge [18] [19] [20] [21] [22] . Some physiopathological hypotheses and autopsy findings supported the likely importance of diffuse pulmonary microthrombosis in the refractory hypoxemia of severe cases [23] [24] [25] [26] , and the crosstalk between the immune and coagulation systems gained importance [27] . Poissy et al reported an increased incidence of pulmonary embolism (PE) [28] , and in subsequent weeks, numerous reports reinforced the high risk of venous thromboembolism (VTE), especially in the intensive care unit (ICU) setting [29] [30] [31] [32] [33] [34] [35] . Later on, arterial thrombotic episodes such as ischemic strokes (IS) and acute coronary syndromes (ACS) were increasingly reported [36] [37] [38] [39] .

The actual incidence of thrombotic events in COVID-19 patients is difficult to assess accurately, as diagnostic and prophylactic strategies have been very heterogeneous worldwide [40] . Recommendation for universal thromboprophylaxis with low-molecular-weight-heparin (LMWH) has been established by international collaborative groups [41, 42] , but the ideal dose is under continuous debate [43] . Some groups, including ours, have used protocols based on LMWH-dose escalation according to clinical severity.

A similar approach was early suggested by some Chinese authors [44] , but it was discarded by most groups around the world due to the inherent risk and lack of evidence. J o u r n a l P r e -p r o o f

Herein we report multiple systemic thrombosis, arteriovenous (common and atypical, macro and microvascular) thromboembolic complications diagnosed in the COVID-19 patient cohort admitted to an academic secondary hospital, the first institution designated as COVID-19-only in Madrid, epicenter of the Spanish outbreak. Database. Data regarding thromboprophylaxis and antiplatelet therapy used in study population prior to the diagnosis of thrombosis were extracted from the Hospital protocol and checked by reviewing medical notes and the Pharmacy registry. During the initial phase of the outbreak (March 3 to March 30), COVID-19 patients were considered acutely-ill medical patients with a standard thrombotic risk, so enoxaparin 40mg subcutaneously (sc) once daily (OD) was recommended, increased to 60mg sc OD on March 31.

Enoxaparin 1mg/kg sc twice daily (BID) was advised if the patient had a precedent indication for chronic anticoagulation or suffered an acute thrombotic event. On the 9th of April, due to the occurrence of fatal strokes and PE cases and recommendations from the Spanish Society of Thrombosis and Hemostasis [46] , a dose-escalating protocol was implemented (Table 1) .

The primary aim was to describe characteristics of patients with a thrombotic complications (arterial, venous or microvascular) in hospitalized patients with COVID-19.

Secondary aims included to analyze clinical and laboratory characteristics , including hemostatic and inflammatory parameters of patients diagnosed with a thrombotic complication. We aimed to compare J o u r n a l P r e -p r o o f Journal Pre-proof difference among patients affected by arterial vs venous events and explore potential predicting prognostic factors between survivors and non-survivors. Although it was not the primary aim of the study, the obtained data allowed to estimate the cumulative incidence (CIn) of thrombotic events among the entire cohort of COVID-19 inpatients.

Thromboprophylaxis protocol. based on a previous report derived from more than 1000 samples in intensive care [52] . A score ≥5 was considered overt DIC.

Characteristics of patients suffering a thrombotic event were analyzed. Although it was not the primary aim of the study, the obtained data allowed to estimate the cumulative incidence (CIn) of thrombotic events among the entire cohort of COVID-19 inpatients. Incidence analysis was performed using Stata 12 (StataCorp LLC, College Station, TX). For these analyses, four thrombotic complications occurring after the discharge of a first ever hospitalization were excluded, thus avoiding a differential follow-up between those patients diagnosed of thrombotic complications and those who were J o u r n a l P r e -p r o o f Figure 2D ), including a 27-year-old healthy man.

Median age of this subgroup was 64 years and 67% were men. Obesity was common (28%), but not other classical VTE risk factors (11%) and a single patient had previous history of VTE. Up to 50% had chronic medical conditions. Median time from COVID-19 symptom onset to VTE diagnosis was 18 days (IQR: [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . In this subgroup, pre-event inflammatory markers tended to be lower.

Co-occurrence of venous and arterial thrombosis: 6 patients suffered both venous and arterial events. Isolated arterial events: 18 patients suffered a total of 24 episodes. Median age was 71 years and 77%

were men. CVRF were prevalent (72% hypertension, 55% former or current smoking, 33% diabetes). Of note, arterial events were diagnosed earlier in the course of the disease: median time from COVID-19 symptom onset to IS was 9 days (IQR: 2-17) and to ACS 11.5 days (IQR: 4-16).

Thirteen patients (median age 76 years, range 55-89) suffered an IS. Only one patient had a history of cerebrovascular disease and, interestingly, all of the events involved large arteries. Seven episodes affected carotid artery depending arteries, 5 vertebrobasilar, and 1 both areas. In 3 patients, 2 or more arterial territories were involved. Intra-arterial thrombus and/or large artery occlusion were observed in 4/6 patients who underwent CT angiography ( Figure 2C ). Only one patient had a previously diagnosed atrial fibrillation, one had a symptomatic carotid artery stenosis and one was found to have floating thrombi in the aortic arch, suggesting embolism; in the remaining cases no stroke etiology was found. Two atypical arterial thrombotic events were diagnosed: a splenic artery thrombosis ( Figure 2E ) and a renal artery thrombosis, causing the infarction of the left kidney ( Figure 2F ).

One patient suffered an acute peripheral artery occlusion in his right distal leg and another 2 developed acro-ischemia due to microvascular thrombosis in fingers and toes (Figure 3 ). One of them suffered from essential thrombocythemia and presented the event in the context of DIC. In both of them, necrotic manifestations appeared 1 month after initial symptoms. 

Platelet count and fibrinogen levels were both elevated, similarly in all subgroups, on admission. During hospitalization, thrombocytopenia was rarely seen and hypofibrinogenemia was sporadically detected in a minority of patients (<3%) in a delayed phase of the disease. In the subgroup of patients with isolated VTE, only one patient died (2%). On the contrary, patients who suffered an arterial event or microvascular ischemia had a significantly higher rate of ICU admission and mortality. Six out of 13 stroke patients died (46%), and 3 developed severe neurological sequelae.

Regarding ACS cases, 3 patients suffered related complications, including a patient who died of cardiac rupture soon after admission.

Potential differences between survivors and non-survivors are detailed in Table 3 .

Interestingly, non-survivors were diagnosed with the thrombotic event earlier in the course of the disease (10.1 vs 18.1 days from symptom onset; p=.02). Univariate analysis revealed arterial thrombotic event, initial ISTH DIC score and pre-event CRP as factors potentially associated with mortality. Peak D-dimer was higher among non-survivors, but not reaching significance. Multivariate analysis including initial DIC score, pre-event CRP, peak D-dimer and thrombotic event subtype (arterial vs others), only confirmed arterial thrombosis as a statistically significant prognostic factor: OR for mortality 18 

Thromboprophylactic protocols

The degree of compliance with the 2 different protocols in the general COVID-19 cohort was 92.5% from March 3 to April 8 and 97.9% from April 9 onwards (when the LMWH-dose escalation protocol was implemented).

Regarding the study group, only 7 patients (10%) were diagnosed with the thrombotic event at the time of admission, so they had received no prophylaxis (4 PE cases and 3 strokes). We confirmed through the Pharmacy registry that the remaining 90% suffered the event despite being on prophylactic enoxaparin as per protocol (40,58% were treated with escalated thromboprophylaxis dosing according to their body weight and renal function) or even on therapeutic LMWH dose (3 patients, 4%). Review of clinical notes ratified that 91.8% and 87.5% of the patients diagnosed with VTE or with an arterial event were under LMWH treatment at the time of diagnosis, respectively ( Table 2, supplementary Table 1 ). Therefore we found no differences among subgroups.

During the study period, only 10 significant hemorrhagic events were registered as in medical records in the general cohort. Six were considered minor (ecchymosis, epistaxis, peri-tracheostomy bleeding) and 4 mayor (a hemorrhagic stroke, 2 low gastrointestinal bleeding and an episode of hematuria). Only one of the patients who suffered a thrombotic event had a relevant bleeding complication while on treatment (a hemorrhagic transformation of an IS).

The incidence of thrombotic events in our large COVID-19 cohort, in patients mainly admitted to general wards, was 6.1% despite quasi-universal thromboprophylaxis,. An Italian single-center study including 388 patients reported a similar incidence of 7.7% [36] , mostly VTE.

The incidence of VTE in our study (4.6%; PE 3.9%, DVT 0.5%) was lower than in other series, with rates of up to 30% [31, 54, 55] . A Dutch study involving 200 patients (DVT screening performed in 28%), reported a 20% incidence of VTE (PE 6.6%; DVT 13.2%) despite routine LMWH prophylaxis [56] . This difference is likely explained by several factors. First, PE was likely underdiagnosed in our cohort during the initial phase of the outbreak due to the exponential growth of cases, unforeseen high risk until J o u r n a l P r e -p r o o f evidence emerged, and practical limitations. Secondly, most of our events were diagnosed in a general ward, where incidence is undoubtedly lower than in the ICU. Lastly, the very high compliance with the recommended protocol and escalating doses might have been effective in reducing events. In our ICU, VTE screening was low due to early initiation of reduced-empirical anticoagulation in many patients.

Isolated arterial events were rare (in accordance with a previous study including 1,400 patients from Madrid [57] ), but they were diagnosed earlier in the course of the disease and were clinically very relevant. The incidence of IS was 1,1%, also similar to other series [58] . We reviewed the incidence of IS and ACS during the same 2-month period for the previous 4 years. There was an age-adjusted 6-fold higher incidence of in-hospital IS during the COVID-19 outbreak, but fewer ACS than in previous years. A similar discrepancy has been reported [36, 59] . Although IS and ACS share risk factors and pathophysiology, hypercoagulability has been linked to a higher risk of IS rather than MI [60, 61] . We might have underdiagnosed coronary events though, as an electrocardiogram was performed on admission but only repeated if there were clinical signs of ACS or arrythmia. Reported incidence of ACS in other series has been higher [62] .

We found a non-negligible number of concomitant arterial and venous events compared to other studies [36, 57] . Scarce reports have described concurrent events [39, 63, 64] , mostly IS and PE, in the absence of classical associated conditions. This probably translates microthrombi formation not only in lung microcirculation, but also in cerebral vessels, possibly facilitated by SARS-CoV-2 neurotropism.

Surprisingly, isolated VTE-diagnosed patients showed a very low mortality rate. Probably because most of EP were peripheral due to microthrombosis in situ. Thrombotic event diagnosis was not associated with increased mortality in the general cohort, in contrast to other similar series [62] , but suffering an arterial event conferred an 18-times higher risk of death compared to VTE.

Non-survivors were diagnosed with thrombosis earlier in the course of the illness, possibly reflecting a more rapidly-progressing systemic disease, or perhaps influenced by the fact that the type of event (arterial in most non-survivors) was clinically more patent than venous episodes.

An acquired syndrome known as COVID-19-associated coagulopathy has emerged and appears to follow

Virchow's Triad [65] . It represents an example of the close interconnection between the immune and coagulation systems [66, 67] . Reported underlying mechanisms include a variety of well-established VTE risk factors [68, 69] , including immobility and severe hypoxemia. However, the high number of events, J o u r n a l P r e -p r o o f concurrent arteriovenous complications, atypical thrombosis including aortic thrombi or portal thrombosis [63, 70, 71] , as in our cohort, clearly suggest that the prothrombotic state is more intense than in other acute and viral illnesses. It is very difficult to define the primary physiopathological event initiating this prothrombotic phase of the disease [72, 73] . Endothelitis might be the key triggering factor [74] [75] [76] [77] , but cytokine-mediated activation of platelets and of the coagulation cascade, decrease of natural anticoagulants or humoral immune-mediated factors such as lupus anticoagulant, might play partial roles.

Hemostatic abnormalities and increased D-dimer have been associated with poor prognosis. Accordingly, we found higher peak D-dimer levels among non-survivors even comparing a subgroup of patients with thrombosis, but without meaning significance. A very small proportion of patients fulfilled ISTH DIC criteria. However, mean initial ISTH score was higher among non-survivors. Multivariate analysis showed that using a cut-off value of ≥3, patients were 4 times more likely to die. Moreover, median pre-event CRP was higher among non-survivors. Therapies targeting the cytokine storm might probably reduce the severity of coagulopathy [65] .

The best thromboprophylactic approach is still unclear [78] , evidence is lacking and international guidelines still recommend standard prophylactic dose [79] . In our study, 90% of the patients suffered the episode despite LMWH. From our accumulated experience during the outbreak, we truly believed that higher doses were required to treat the likely influence of pulmonary microthrombosis on severe hypoxemia and to prevent thrombotic events.

A recently published retrospective study from New York of over 3,300 patients, reported an incidence of 16% and 11,5% of any thrombotic event in the general cohort and in the non-ICU cohort, respectively.

Screening was not standard, similar to our approach, but low-dose-standard-thromboprophylaxis was used [62] . In our study, incidence was clearly lower, but we were only able to describe indirect data suggesting a beneficial effect of higher LMWH dose in reducing events.

Our study has several limitations. Its retrospective nature, coming from a single-center cohort, and the changing practicing conditions during different phases of the outbreak, that influenced the diagnostic, prophylactic and therapeutic protocols. VTE incidence was probably underestimated as DVT screening was limited to PE diagnosed cases or patients with clinical signs of DVT, PE risk was initially unrecognized, and there was no active search in the ICU due to escalated-thromboprophylaxis and procedural constraints.

We were unable to analyze the potential effect of LMWH on mortality. Dose was variable in some patients J o u r n a l P r e -p r o o f depending on the clinical situation, and there were too many potential confounders (fewer admissions/day, higher steroid use, optimized ventilator-support circuit, accumulated experience, etc.) that could affect mortality and for which we could not adjust.

We demonstrated the occurrence of typical and atypical arterial and venous thrombotic events despite quasi-universal optimized or even escalated thromboprophylaxis, in a large cohort of COVID-19 patients.

Arterials events tend to appear early in the course of the illness and they confer poor prognosis. Even in patients with proven thrombotic events, DIC is not common, but an ISTH DIC score ≥3 at presentation was identified as a potential predictor of mortality. Levels of CRP and D-dimer, reflecting the hyperinflammatory and thrombogenic phases of the disease, were higher among non-survivors. A highdose thromboprophylactic protocol seemed to reduce the rate of thrombotic events and might have played a role in lowering mortality among other factors, with a low incidence of hemorrhagic complications.

Therefore, patients with severe COVID-19 may benefit from severity-adjusted thromboprophylaxis and multicenter randomized controlled trials are eagerly awaited (NCT04372589, NCT04367831, NCT04345848, and NCT04366960). 

The authors declare they have no conflict of interest

Report of clustering pneumonia of unknown etiology in Wuhan City

WHO. Novel Coronavirus (2019-nCoV) SITUATION REPORT -1 21

Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention

Virtual press conference on COVID-19 -11

Coronavirus disease (COVID-19) Situation Report -178

Worldmeter COVID-19 Data

Centro de Coordinación de Alertas y Emergencias Sanitarias. Ministerio de Sanidad

Novel Coronavirus(2019-nCoV) Situation Report -22. World Health Organization

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Epidemiological and clinical characteristics of 99 cases of

China: a descriptive study

Prominent changes in blood coagulation of patients with SARS-CoV-2 infection

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease

D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis

Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Acute pulmonary embolism and COVID-19 pneumonia: a random association?

Acute Pulmonary Embolism in COVID-19 Patients on CT Angiography and Relationship to D-Dimer Levels

Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia

The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome

Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis

Are subpleural consolidations indicators for segmental pulmonary embolism in COVID-19?

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Pulmonary post-mortem findings in a large series of COVID-19 cases from Northern Italy. J o u r n a l P r e -p r o o f Infectious Diseases (except HIV/AIDS)

Cross Talk Pathways Between Coagulation and Inflammation

Pulmonary Embolism in COVID-19 Patients: Awareness of an Increased Prevalence

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Incidence of venous thromboembolism in hospitalized patients with COVID-19

Findings of Acute Pulmonary Embolism in COVID-19 Patients

COVID-19 Complicated by Acute Pulmonary Embolism

Venous Thrombosis Among Critically Ill Patients With Coronavirus Disease 2019 (COVID-19)

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young

ST-Segment Elevation in Patients with Covid-19 -A Case Series

Pulmonary, Cerebral, and Renal Thromboembolic Disease Associated with COVID-19 Infection

Thrombosis risk associated with COVID-19 infection. A scoping review

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

COVID-19 and its implications for thrombosis and anticoagulation

Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia

Case definition for coronavirus disease 2019 (COVID-19), as of 29

Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support

The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators

ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the

Towards Definition

The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview

Use of soluble fibrin antigen instead of D-dimer as fibrin-related marker may enhance the prognostic power of the ISTH overt DIC score

Cumulative Incidence Estimation in the Presence of Competing Risks

Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected by Pulmonary CT Angiography

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis

Incidence of venous thromboembolism in hospitalized patients with COVID-19

Incidence and consequences of systemic arterial thrombotic events in COVID-19 patients

Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Hypercoagulability Is a Stronger Risk Factor for Ischaemic Stroke than for Myocardial Infarction: A Systematic Review

Hypercoagulability and the risk of myocardial infarction and ischemic stroke in young women

Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System

Concomitant acute aortic thrombosis and pulmonary embolism complicating COVID-19 pneumonia

Severe arterial thrombosis associated with Covid-19 infection

COVID-19 update: Covid-19-associated coagulopathy

Bidirectional Relation Between Inflammation and Coagulation

Thromboinflammation and the hypercoagulability of COVID-19

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Concomitant brain arterial and venous thrombosis in a COVID-19 patient

Portal vein thrombosis in a patient with COVID-19

Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation

Thromboinflammation and the hypercoagulability of COVID-19

COVID-19: the vasculature unleashed

Endothelial cell infection and endotheliitis in COVID-19

Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy

Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified?

Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report

Fibrinogen *, mg/dL, median (IQR)

ISTH DIC score *, mean (SD)

Creatinine *, mg/dL, median (IQR)

Pre-event IL-6, pg/mL, median (IQR) 109

Pre-event Ferritin, ng/mL, median (IQR)

Pre-event CRP, mg/L, median (IQR) *, cells x10³/mm³, median (IQR)

ISTH DIC score *, mean (SD)

Pre-event ISTH DIC score, mean (SD)

Creatinine *, mg/dL, median (IQR)

Pre-event IL-6, pg/mL, median (IQR)

Pre-event Ferritin, ng/mL, median (IQR)

Pre-event CRP, mg/L, median (IQR)

 Table 1 . Description of 80 thrombotic events in 69 patients with COVID-19-associated thromboembolic disease. Submitted separately.Supplementary material: Table A . Cumulative incidence (% and 95% CI) of thrombosis among 1,127 inpatients during a first ever admission because of COVID-19, multiple decrement model with death as a competing risk. CI, confidence interval; N, number of subjects; NA, not applicable. Active cancer, n (%) 1 (5) 4 (9) 0 0 5 (7) 1 (13) <0.001 VTE: Venous thromboembolism. RAAS: Renin-Angiotensin-Aldosterone System. ISTH: International Society of Thrombosis and Haemostasis. DIC score: overt Disseminated Intravascular Coagulation score. IL-6: Interleukin 6. CRP: C reactive protein. LMWH: Low-molecular-weight heparin. ICU: Intensive care unit. IQR: Interquartile range. * Initial laboratory investigation, on presentation. † As per described protocol or due to a precedent chronic condition requiring anticoagulation. Low-molecular-weight heparin. * Initial laboratory investigation, on presentation. † ISTH DIC score increment: Pre-event score minus initial score. ‡ As per described protocol or due to a precedent chronic condition requiring anticoagulation.